about
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor modelRictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survivalSynthetic lethality in lung cancer and translation to clinical therapiesNano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivoInduction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancerSuppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicitiesSphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour modelsThe formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles.Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems.Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo ModelLiposomal drug delivery: recent patents and emerging opportunities.Identification of breast cancer cell subtypes sensitive to ATG4B inhibition.Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells.Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma.Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.Chemodosimetry of in vivo tumor liposomal drug concentration using MRI.Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line.Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems.Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese.An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol.Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer.Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes.
P50
Q21133610-1D9CA85A-7910-451D-A1C6-49DF55B41BEFQ24310871-322053D2-44DD-4AC9-9A04-038FBA99F225Q28072904-F221A543-DAB1-4BAE-B0F2-750D09E7FE42Q28488457-34E9F9F4-9EAA-4157-9CD1-1ED613389C56Q28534358-0758CC3C-5C6D-4419-B1CF-4996979062C7Q34430583-7963509B-F956-4EA2-BA8E-08EF8258DFF1Q34484362-033EAFB4-FEB4-4E0B-B753-E6B4B852AE99Q36081662-162A2AA6-AE8C-41EF-BEAF-74C1C85A6815Q36320804-30B42E6A-18EC-462C-B8CB-D130AA4380CCQ36356990-2CF80162-0BA8-4424-99E8-607FD2D3CAF8Q36569929-7E4E34EB-90D0-4717-BAD0-C17E00518880Q36720975-CB6E2940-A6FA-439D-84D2-3814EDE231CDQ37347794-2CDE3BB4-40BC-421C-8546-CA06ABAF5352Q37687104-B963C08C-018F-4134-9179-DE76DAE587C9Q38205584-387A008F-0E63-4605-9B42-E59D5EBE4C08Q38287723-0A0E6B3F-5D82-4D76-ACD6-4367969F1820Q38292205-F989B27C-47BB-48C3-AB59-40B847D8C5AFQ38667138-8B9B7AFD-918E-45A2-84E9-373725FD0A06Q38822576-A6F154AF-5A23-48EC-8D3D-238886565199Q38825522-A14E008B-BA2B-43DC-9317-707433A7A0B5Q38848421-A067E4F7-5723-461E-81CB-552DB8298C7CQ39332189-A17718A8-18C1-4484-A9B2-60872FBCF29EQ39457556-FEA9F18A-7394-4081-8D70-01D218F05F62Q39574525-C2A649CC-51FD-40BA-B1F6-FCEAE8D38AD5Q40161462-E9EC8F39-7DD3-4061-A275-D70370594C53Q40222329-38CD5AC3-452A-4859-94EF-1456E8866387Q40226151-375D095A-D0F1-42D7-BE2D-5EB4259D46A4Q40369209-6E493239-9CEB-4D68-B06E-BAD59D87A338Q40486768-62DB65A9-98AA-46ED-85A5-101E250E249FQ40505774-773F7FD7-84F6-41DB-87D9-788B3350E7FCQ40593412-318174E2-A0D5-4EC5-A8C7-E26A7EDB44B7Q40658902-E05FD43A-AFCF-4DBF-A528-C90A465D5C18Q41624755-90542BF1-57BD-4AFE-8F6C-43D60CF8DEF7Q41627241-E99A4B22-53C1-443D-A9A2-9525F4003852Q41628394-06754AFC-49CE-4E30-AC6C-BFCE2AC2C449Q41628664-B54C8122-C3E8-4D0E-86B1-E4B3FB274792Q41630238-DD436141-872D-483D-82D6-1C21DCAAEC0CQ42220334-00862A1E-E9B7-4FCF-A253-3A5B21DCEEB1Q42317502-9383EBB4-D344-4B32-8491-807EF421BC1DQ43685718-0241B33D-8B5C-4526-97AC-CA66CA1A425D
P50
description
researcher ORCID ID = 0000-0002-1994-4787
@en
wetenschapper
@nl
name
Marcel B Bally
@ast
Marcel B Bally
@en
Marcel B Bally
@es
Marcel B Bally
@nl
type
label
Marcel B Bally
@ast
Marcel B Bally
@en
Marcel B Bally
@es
Marcel B Bally
@nl
prefLabel
Marcel B Bally
@ast
Marcel B Bally
@en
Marcel B Bally
@es
Marcel B Bally
@nl
P1153
7006109241
P21
P31
P496
0000-0002-1994-4787